Cyclerion Therapeutics to Host Pipeline Update Webinar
20 avr. 2021 07h00 HE
|
Cyclerion Therapeutics, Inc.
Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS Neuropsychiatric key opinion leader, Andreas Reif,...
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
25 févr. 2021 07h00 HE
|
Cyclerion Therapeutics, Inc.
Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers...
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
25 janv. 2021 07h00 HE
|
Cyclerion Therapeutics, Inc.
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 ...